Search results

A desire to give people around the world greater access to the benefits of nuclear medicine is behind Robert Raposio and his research into producing radioisotopes in more efficient, cheaper and sustainable ways.

On behalf of ANSTO thank you for your interest in our tours. We hope your visit to ANSTO will be both enjoyable and informative.

Nuclear techniques will be crucial tools in the development of advanced materials that sustainably convert waste heat into useful forms of energy to benefit Australia.

CORIS360® GNI images gamma-ray and thermal neutron radiation sources, delivering an unprecedented ability to detect, localise, and identify nuclear materials.

A team of Australian scientists have created a new portable device that can pinpoint the exact location of radiation sources, faster and more accurately than ever before.

ANSTO is taking its innovative ANSTO Synroc® and CORIS360® technologies to the world stage at the Waste Management Symposia 2024 in Phoenix, Arizona USA this week (10 – 14 March 2024). Joining over 45 other countries and around 3,000 attendees, an Australian Government contingent comprising of ANSTO and the Australian Radioactive Waste Agency is in attendance to showcase Australia’s extensive radioactive waste management capabilities.

CORIS360 delivers fast, accurate radiation detection and imaging, making invisible radiation visible to improve safety and decision making in radioactive environments.

Commitment to undertake health research.

The Detection & Imaging group builds on ANSTO’s 70-year history of scientific achievements and contributions in meeting the nuclear needs of industry, globally.

In April 15, 1953, Australia entered the nuclear science arena, when the Atomic Energy Act came into effect. The Australian Atomic Energy Commission (AAEC) followed and in 1987 the AAEC evolved into the Australian Nuclear Science and Technology Organisation (ANSTO) as it’s known today.

Update on Nuclear medicine production at ANSTO.

Use of nuclear techniques to benefit industry and consumers

ANSTO is proud to announce that a license has been issued by the Therapeutic Goods Administration to produce Lutetium-177 (Lu-177) for use in clinical trials.